These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31119414)

  • 1. A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of
    Wang SJ; Huang WS; Chuang CM; Chang CH; Lee TW; Ting G; Chen MH; Chang PM; Chao TC; Teng HW; Chao Y; Chen YM; Lin TP; Chang YJ; Chen SJ; Huang YR; Lan KL
    EJNMMI Res; 2019 May; 9(1):46. PubMed ID: 31119414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.
    Tsai CC; Chang CH; Chen LC; Chang YJ; Lan KL; Wu YH; Hsu CW; Liu IH; Ho CL; Lee WC; Ni HC; Chang TJ; Ting G; Lee TW
    Int J Nanomedicine; 2011; 6():2607-19. PubMed ID: 22114492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model.
    Chen LC; Wu YH; Liu IH; Ho CL; Lee WC; Chang CH; Lan KL; Ting G; Lee TW; Shien JH
    Nucl Med Biol; 2012 Jan; 39(1):35-43. PubMed ID: 21958858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the therapeutic and diagnostic effects of PEGylated liposome-embedded 188Re on human non-small cell lung cancer using an orthotopic small-animal model.
    Lin LT; Chang CH; Yu HL; Liu RS; Wang HE; Chiu SJ; Chen FD; Lee TW; Lee YJ
    J Nucl Med; 2014 Nov; 55(11):1864-70. PubMed ID: 25349220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts.
    Hsu CW; Chang YJ; Chang CH; Chen LC; Lan KL; Ting G; Lee TW
    Cancer Biother Radiopharm; 2012 Oct; 27(8):481-9. PubMed ID: 23067100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
    Lam K; Chan C; Done SJ; Levine MN; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.
    Huang FY; Lee TW; Chang CH; Chen LC; Hsu WH; Chang CW; Lo JM
    Int J Nanomedicine; 2015; 10():463-73. PubMed ID: 25624760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution, pharmacokinetics, and organ-level dosimetry for
    Esquinas PL; Shinto A; Kamaleshwaran KK; Joseph J; Celler A
    EJNMMI Phys; 2018 Dec; 5(1):30. PubMed ID: 30523435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric evaluation of nanotargeted (188)Re-liposome with the MIRDOSE3 and OLINDA/EXM programs.
    Chang CH; Chang YJ; Lee TW; Ting G; Chang KP
    Ann Nucl Med; 2012 Jun; 26(5):419-25. PubMed ID: 22450826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
    Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internal dosimetry and biodistribution of indigenously prepared 177Lu-DOTA-rituximab in lymphoma and other hematological malignancies treated with rituximab.
    Edamadaka Y; Parghane RV; Sahu S; Lad S; Kamaldeep ; Wanage G; Shanmukhaiah C; Kulkarni V; Basu S
    Nucl Med Commun; 2024 Jun; ():. PubMed ID: 38975801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice.
    Chen MH; Chang CH; Chang YJ; Chen LC; Yu CY; Wu YH; Lee WC; Yeh CH; Lin FH; Lee TW; Yang CS; Ting G
    Anticancer Res; 2010 Jan; 30(1):65-72. PubMed ID: 20150618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy.
    Chang CH; Stabin MG; Chang YJ; Chen LC; Chen MH; Chang TJ; Lee TW; Ting G
    Cancer Biother Radiopharm; 2008 Dec; 23(6):749-58. PubMed ID: 19111045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.
    Lin YY; Chang CH; Li JJ; Stabin MG; Chang YJ; Chen LC; Lin MH; Tseng YL; Lin WJ; Lee TW; Ting G; Chang CA; Chen FD; Wang HE
    Cancer Biother Radiopharm; 2011 Jun; 26(3):373-80. PubMed ID: 21711113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
    Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
    Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
    Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
    J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
    [No Abstract]   [Full Text] [Related]  

  • 18. Biodistribution and radiation dosimetry of [
    Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
    Emfietzoglou D; Kostarelos K; Sgouros G
    J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
    J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.